Skip to main content
Clinical Trials/NCT00195273
NCT00195273
Completed
Phase 3

A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors

Wyeth is now a wholly owned subsidiary of Pfizer0 sites61 target enrollmentNovember 2004

Overview

Phase
Phase 3
Intervention
sirolimus
Conditions
Graft vs Host Disease
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
61
Primary Endpoint
Mean Creatinine Clearance Rate
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted patients treated with cyclosporine, mycophenolate and corticosteroids.

Registry
clinicaltrials.gov
Start Date
November 2004
End Date
July 2008
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • Kidney transplantation
  • Donor must be at least 60 years old.

Exclusion Criteria

  • Current systemic infection
  • Unstable angina or treatment for serious arrhythmia.
  • Cancer within the previous 5 years.

Arms & Interventions

1

Sirolimus + Daclizumab + Mycophenolate + Corticosteroids

Intervention: sirolimus

1

Sirolimus + Daclizumab + Mycophenolate + Corticosteroids

Intervention: mycophenolate mofetil

1

Sirolimus + Daclizumab + Mycophenolate + Corticosteroids

Intervention: corticosteroids

1

Sirolimus + Daclizumab + Mycophenolate + Corticosteroids

Intervention: daclizumab

2

Cyclosporine + Mycophenolate + Corticosteroids

Intervention: cyclosporine

2

Cyclosporine + Mycophenolate + Corticosteroids

Intervention: mycophenolate mofetil

2

Cyclosporine + Mycophenolate + Corticosteroids

Intervention: corticosteroids

Outcomes

Primary Outcomes

Mean Creatinine Clearance Rate

Time Frame: 12 months

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.

Secondary Outcomes

  • Number of Patients With Acute Rejection(3 and 12 months)
  • Patient and Graft Survival(12 months)
  • Mean Creatinine Clearance Rate - 3 Months(3 months)

Similar Trials